Hapvida Participacoes e Investimentos (HAPV3) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
Q3 revenue rose 3.9% YoY to R$8.08bn, while adjusted EBITDA fell 33.5% to R$496.6m amid higher cash MLR and civil contingencies.
Turnaround priorities include deleveraging, repricing, cost reduction and customer experience; management expects clearer results from H1 2027.
Q3 results were pressured by litigation, runoff claims, seasonality and optimization costs; management said performance was below acceptable levels.
Financial highlights
Q3 net revenue was R$8,080.0m, up 1.3% QoQ and 3.9% YoY; 9M revenue was R$23,946.3m, up 4.3%.
Adjusted EBITDA was R$496.6m, down 1.5% QoQ and 33.5% YoY; 9M adjusted EBITDA was R$1,804.3m, down 32.1%.
Net loss was R$118.8m versus R$57.0m in 3Q25; adjusted net income was R$107.0m, down 68.3% YoY.
Gross profit was R$1,587.2m, with a 19.6% margin, down 157 bps YoY; operating income was R$37.4m, down 77.9%.
Outlook and guidance
Transformation initiatives are expected to have a more significant impact from H1 2027; priorities include cash generation, deleveraging, margin recovery and customer experience.
Contract renegotiations and review of underperforming lives aim to improve margins and cash generation; structural network initiatives are intended to support MLR improvement while preserving care quality.
Commercial, operational and administrative cost actions are expected to yield gains through 2027; the first zero-based budget is planned for 2027.
Q4 milestones include fewer new court-ordered blocks, progress on ~700,000 lives under review, higher ticket and healthier sales.
Latest events from Hapvida Participacoes e Investimentos
- Adjusted EBITDA rose as leverage fell to 1.38x despite beneficiary attrition.HAPV3
Q4 2023 - Revenue up 3.9% YoY, but EBITDA and net income down amid margin and litigation pressures.HAPV3
Q2 2026 - Net revenue rose 5.2% YoY to R$7.9B, with EBITDA at R$803M and improved cash MLR.HAPV3
Q1 2026 - Net revenue up 5.9% YoY, but margin and beneficiary base declined amid cost and competitive pressures.HAPV3
Q4 2025 - Net revenue up 6.0% YoY, adjusted EBITDA at R$746.4M, and cash MLR at 75.2%.HAPV3
Q3 2025 - Net revenue rose 7.3% to R$7.67B, with strong beneficiary growth and resilient margins.HAPV3
Q2 2025 - Revenue and margins improved, with net debt at 0.97x EBITDA and strong cash flow.HAPV3
Q3 2024 - Strong revenue and margin growth, improved cash flow, and reduced liabilities in 2024.HAPV3
Q4 2024 - Revenue up 7.3% YoY, leverage down to 0.98x, but adjusted net income declined on legal costs.HAPV3
Q1 2025